BioInvent International AB (publ) (BINV.ST)
SEK 39.75
(2.45%)
SEK 39.75
(2.45%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 71.46 Million SEK | -78.09% |
| 2022 | 326.12 Million SEK | 1582.45% |
| 2021 | 19.38 Million SEK | -86.85% |
| 2020 | 147.37 Million SEK | 57.21% |
| 2019 | 93.74 Million SEK | 143.18% |
| 2018 | 38.54 Million SEK | -14.36% |
| 2017 | 45.01 Million SEK | -36.85% |
| 2016 | 71.28 Million SEK | 347.62% |
| 2015 | 15.92 Million SEK | -66.07% |
| 2014 | 46.93 Million SEK | -42.56% |
| 2013 | 81.71 Million SEK | 90.27% |
| 2012 | 42.94 Million SEK | -65.55% |
| 2011 | 124.64 Million SEK | 50.42% |
| 2010 | 82.86 Million SEK | 2.74% |
| 2009 | 80.65 Million SEK | -68.01% |
| 2008 | 252.13 Million SEK | 75.78% |
| 2007 | 143.43 Million SEK | 182.2% |
| 2006 | 50.82 Million SEK | 80.26% |
| 2005 | 28.19 Million SEK | -52.0% |
| 2004 | 58.74 Million SEK | -11.94% |
| 2003 | 66.71 Million SEK | -23.36% |
| 2002 | 87.05 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 12.76 Million SEK | 176.82% |
| 2024 Q1 | 5.94 Million SEK | -61.21% |
| 2024 Q2 | 4.61 Million SEK | -22.4% |
| 2023 Q3 | 26.79 Million SEK | 104.64% |
| 2023 Q2 | 13.09 Million SEK | -19.42% |
| 2023 Q1 | 16.25 Million SEK | -21.27% |
| 2023 FY | 71.46 Million SEK | -78.09% |
| 2023 Q4 | 15.31 Million SEK | -42.83% |
| 2022 Q2 | 270.9 Million SEK | 1526.19% |
| 2022 FY | 326.12 Million SEK | 1582.45% |
| 2022 Q4 | 20.64 Million SEK | 15.18% |
| 2022 Q3 | 17.92 Million SEK | -93.39% |
| 2022 Q1 | 16.65 Million SEK | 239.77% |
| 2021 Q4 | 4.9 Million SEK | 63.82% |
| 2021 Q2 | 5.28 Million SEK | -14.71% |
| 2021 FY | 19.38 Million SEK | -86.85% |
| 2021 Q3 | 2.99 Million SEK | -43.4% |
| 2021 Q1 | 6.2 Million SEK | -93.72% |
| 2020 Q1 | 16.71 Million SEK | -34.16% |
| 2020 Q2 | 15.64 Million SEK | -6.38% |
| 2020 Q4 | 98.74 Million SEK | 507.01% |
| 2020 Q3 | 16.26 Million SEK | 3.96% |
| 2020 FY | 147.37 Million SEK | 57.21% |
| 2019 Q1 | 17.4 Million SEK | 67.7% |
| 2019 FY | 93.74 Million SEK | 143.18% |
| 2019 Q3 | 18.05 Million SEK | -45.12% |
| 2019 Q4 | 25.38 Million SEK | 40.62% |
| 2019 Q2 | 32.89 Million SEK | 89.05% |
| 2018 Q1 | 11.33 Million SEK | -16.28% |
| 2018 Q2 | 9.79 Million SEK | -13.58% |
| 2018 FY | 38.54 Million SEK | -14.36% |
| 2018 Q3 | 7.04 Million SEK | -28.05% |
| 2018 Q4 | 10.37 Million SEK | 47.28% |
| 2017 Q4 | 13.53 Million SEK | 89.55% |
| 2017 Q3 | 7.14 Million SEK | -37.16% |
| 2017 Q1 | 12.97 Million SEK | -57.86% |
| 2017 FY | 45.01 Million SEK | -36.85% |
| 2017 Q2 | 11.36 Million SEK | -12.4% |
| 2016 FY | 71.28 Million SEK | 347.62% |
| 2016 Q3 | 812 Thousand SEK | -92.12% |
| 2016 Q2 | 10.3 Million SEK | -64.93% |
| 2016 Q1 | 29.37 Million SEK | 194.26% |
| 2016 Q4 | 30.78 Million SEK | 3691.75% |
| 2015 Q4 | 9.98 Million SEK | 498.56% |
| 2015 FY | 15.92 Million SEK | -66.07% |
| 2015 Q3 | 1.66 Million SEK | -54.4% |
| 2015 Q2 | 3.65 Million SEK | 494.8% |
| 2015 Q1 | 615 Thousand SEK | -63.22% |
| 2014 Q2 | 32.44 Million SEK | 1739.12% |
| 2014 Q4 | 1.67 Million SEK | -84.87% |
| 2014 Q1 | 1.76 Million SEK | -96.47% |
| 2014 FY | 46.93 Million SEK | -42.56% |
| 2014 Q3 | 11.05 Million SEK | -65.93% |
| 2013 Q4 | 49.98 Million SEK | 539.43% |
| 2013 Q2 | 12.27 Million SEK | 5.46% |
| 2013 FY | 81.71 Million SEK | 90.27% |
| 2013 Q1 | 11.63 Million SEK | 25.11% |
| 2013 Q3 | 7.81 Million SEK | -36.31% |
| 2012 Q1 | 14.5 Million SEK | 689.82% |
| 2012 Q3 | 12.88 Million SEK | 106.31% |
| 2012 Q4 | 9.3 Million SEK | -27.82% |
| 2012 FY | 42.94 Million SEK | -65.55% |
| 2012 Q2 | 6.24 Million SEK | -56.94% |
| 2011 Q4 | 1.83 Million SEK | -74.35% |
| 2011 Q3 | 7.16 Million SEK | -60.84% |
| 2011 Q2 | 18.29 Million SEK | -81.21% |
| 2011 Q1 | 97.35 Million SEK | 1404.03% |
| 2011 FY | 124.64 Million SEK | 50.42% |
| 2010 FY | 82.86 Million SEK | 2.74% |
| 2010 Q4 | 6.47 Million SEK | -51.41% |
| 2010 Q3 | 13.32 Million SEK | -72.46% |
| 2010 Q2 | 48.36 Million SEK | 220.28% |
| 2010 Q1 | 15.1 Million SEK | -24.61% |
| 2009 Q3 | 13.5 Million SEK | 24.41% |
| 2009 Q2 | 10.85 Million SEK | -70.54% |
| 2009 FY | 80.65 Million SEK | -68.01% |
| 2009 Q4 | 20.03 Million SEK | 48.3% |
| 2009 Q1 | 36.84 Million SEK | 0.0% |
| 2008 FY | 252.13 Million SEK | 75.78% |
| 2007 FY | 143.43 Million SEK | 182.2% |
| 2006 FY | 50.82 Million SEK | 80.26% |
| 2005 FY | 28.19 Million SEK | -52.0% |
| 2004 FY | 58.74 Million SEK | -11.94% |
| 2003 FY | 66.71 Million SEK | -23.36% |
| 2002 FY | 87.05 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | -22.982% |
| Ziccum AB (publ) | 3.74 Million SEK | -1807.152% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 88.399% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | -41.549% |
| Mendus AB (publ) | 28.48 Million SEK | -150.855% |
| Genovis AB (publ.) | 158.23 Million SEK | 54.838% |
| Intervacc AB (publ) | 8.01 Million SEK | -791.591% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -1533.768% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 58.073% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | -62.796% |
| Aptahem AB (publ) | 2.63 Million SEK | -2616.479% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -6804.444% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -92706.494% |
| Fluicell AB (publ) | 3.33 Million SEK | -2040.833% |
| Saniona AB (publ) | 16.84 Million SEK | -324.353% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | -335.552% |
| Biovica International AB (publ) | 7.29 Million SEK | -880.261% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -5840.233% |
| AcouSort AB (publ) | 10.55 Million SEK | -577.291% |
| Xintela AB (publ) | 78 Thousand SEK | -91516.667% |
| Abliva AB (publ) | 137 Thousand SEK | -52061.314% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | -24.064% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -3448.213% |
| OncoZenge AB (publ) | 3000.00 SEK | -2381933.333% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -46003.871% |
| CombiGene AB (publ) | 5.54 Million SEK | -1188.952% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 94.079% |
| Camurus AB (publ) | 1.71 Billion SEK | 95.838% |
| Corline Biomedical AB | 25.03 Million SEK | -185.501% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -1158.559% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -9811.373% |
| I-Tech AB | 120.86 Million SEK | 40.873% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 46.708% |
| Cyxone AB (publ) | 5.14 Million SEK | -1288.131% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -913.631% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | -570.07% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | -536.337% |
| Nanologica AB (publ) | 1.44 Million SEK | -4852.252% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -134732.075% |
| Alzinova AB (publ) | 270 Thousand SEK | -26367.037% |
| Oncopeptides AB (publ) | 35.22 Million SEK | -102.899% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -4784.486% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -2432.282% |
| Simris Alg AB (publ) | 4.35 Million SEK | -1541.272% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -54870.0% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 70.066% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -310600.0% |